Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PA5 in Advanced Solid Tumors
NCT07702162Phase 1Recruiting
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
- Start
- Nov 2025
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in solid tumor, sponsored by Chongqing Peg-Bio Biopharm Co., Ltd. Primary endpoints: Incidence of dose limiting toxicity at 4 weeks, Maximum tolerated dose at 4 weeks and 2 more. Started Nov 2025; status: recruiting.
02
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07702162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07702162.